Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine and Gemcitabine vs Capecitabine in Metastatic Breast Cancer
NCT00431106Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Apr 2002
- Primary completion
- Jan 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Vinorelbine/Gemcitabine (VG) with Capecitabine (Cap) (2 arms). Primary endpoint: Time to tumor progression at 1 year. Started Apr 2002; status: completed.
02
Drugs
vinorelbinegemcitabinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00431106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431106.